From Financial Modeling Prep: 2025-04-22 15:00:00

ResMed (NYSE:RMD) is a key player in the healthcare industry, specializing in sleep disorder equipment. Analysts predict an EPS of $2.36 and revenue of $1.28 billion for their upcoming quarterly earnings report on April 23, 2025.

The expected EPS of $2.36 marks a 10.8% increase from last year, with revenue projected to rise by 7.3% compared to the same quarter in the previous year. Despite a slight 0.1% downward revision in EPS estimates, ResMed’s growth trajectory remains positive.

ResMed’s strong financial standing is evident through its low debt-to-equity ratio of 0.16 and impressive current ratio of 3.33. These figures indicate a stable financial structure and the ability to cover short-term liabilities with assets.

Investors are eagerly awaiting ResMed’s earnings report, as surpassing EPS and revenue estimates could boost stock prices. Conversely, falling short may lead to a decline. Management’s insights during the earnings call will be crucial in assessing future performance and stock movement.



Read more at Financial Modeling Prep:: ResMed (NYSE:RMD) Quarterly Earnings Preview